系统性红斑狼疮患者与匹配对照的死亡率、死因及药物影响
SLE患者全因死亡率是对照的1.80倍(95%CI 1.57-2.08),18-39岁组风险最高(HR=4.87),累积糖皮质激素使用升高死亡率,低剂量羟氯喹累积使用使风险降低45%。
要点
- SLE患者全因死亡率显著高于匹配对照(校正HR=1.80)。
- 18-39岁年轻SLE患者死亡风险最高(校正HR=4.87)。
- 累积低剂量羟氯喹使用与死亡率降低45%相关。
核心结论
- 英国SLE患者全因死亡率约为一般人群的1.8倍,年轻发病和糖皮质激素使用与死亡风险增加相关,低剂量羟氯喹累积使用显著降低死亡率。
主要发现
- SLE患者全因死亡率较年龄性别匹配对照升高1.8倍(校正HR=1.80,95%CI 1.57-2.08)。
- 18-39岁SLE患者死亡风险最高(校正HR=4.87,95%CI 1.93-12.3)。
- 男性和女性SLE患者死亡率无显著差异。
- 累积糖皮质激素使用升高死亡率,而累积低剂量羟氯喹使用使风险降低45%。
- SLE患者心血管疾病、感染、非感染性呼吸系统疾病及事故或自杀归因死亡的特异死亡率升高,而癌症死亡率较对照降低。
临床怎么用
- 临床应关注SLE患者尤其是年轻发病者的死亡风险,优化糖皮质激素使用并重视低剂量羟氯喹的累积暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We wanted to estimate the magnitude of the risk from all-cause, cause-specific and sex-specific mortality in patients with SLE and relative risks compared with matched controls and to evaluate the influence of exposure to medication on risk of mortality in SLE. METHODS: We conducted a population-based cohort study using the Clinical Practice Research Datalink, Hospital Episode Statistics and national death certificates (from 1987 to 2012). Each SLE patient (n = 4343) was matched with up to six controls (n = 21 780) by age and sex. Cox proportional hazards models were used to estimate overall and cause-specific mortality rate ratios. RESULTS: Patients with SLE had a 1.8-fold increased mortality rate for all-cause mortality compared with age- and sex-matched subjects [adjusted hazard ratio (HR) = 1.80, 95% CI: 1.57, 2.08]. The HR was highest in patients aged 18-39 years (adjusted HR = 4.87, 95% CI: 1.93, 12.3). Mortality rates were not significantly different between male and female patients. Cumulative glucocorticoid use raised the mortality rate, whereas the HR was reduced by 45% with cumulative low-dose HCQ use. Patients with SLE had increased cause-specific mortality rates for cardiovascular disease, infections, non-infectious respiratory disease and for death attributable to accidents or suicide, whereas the mortality rate for cancer was reduced in comparison to controls. CONCLUSION: British patients with SLE had a 1.8-fold increased mortality rate compared with the general population. Glucocorticoid use and being diagnosed at a younger age were associated with an increased risk of mortality. HCQ use significantly reduced the mortality rate, but this association was found only in the lowest cumulative dosage exposure group.
引用
- Bultink IEM, de Vries F, van Vollenhoven RF, et al. Mortality, causes of death and influence of medication use in patients with systemic lupus erythematosus vs matched controls. Rheumatology (Oxford). 2021. PMID: 32653901. doi:10.1093/rheumatology/keaa267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。